Dr Reddy's to market three of Amgen's drugs in India

6 August 2015

Indian drug major Dr Reddy's Laboratories (NYSE:RDY) has entered into a strategic collaboration with USA-based Amgen (Nasdaq: AMGN) – a leading independent biotechnology company – to market and distribute three Amgen drugs in India in the areas of oncology and cardiology.

Dr Reddy's shares on Thursday surged as much as 3.2% to hit a 52-week high of 4,326.5 rupees after the announcement. Analysts say the collaboration with Amgen may result in increased revenues for Dr Reddy's Laboratories.

Deal covers Kyprolis, Blincyto and Repatha

Under the terms of the collaboration, financial aspects of which were not disclosed, Dr Reddy’s will perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), Blincyto (blinatumomab) and Repatha (evolocumab) in India. The accord leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr Reddy’s deep understanding of patient and physician needs in India, the company said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK